David C. Turner

7.3k total citations · 1 hit paper
123 papers, 5.5k citations indexed

About

David C. Turner is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, David C. Turner has authored 123 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Biology, 36 papers in Oncology and 23 papers in Cell Biology. Recurrent topics in David C. Turner's work include Cell Adhesion Molecules Research (20 papers), CAR-T cell therapy research (15 papers) and Lipid Membrane Structure and Behavior (15 papers). David C. Turner is often cited by papers focused on Cell Adhesion Molecules Research (20 papers), CAR-T cell therapy research (15 papers) and Lipid Membrane Structure and Behavior (15 papers). David C. Turner collaborates with scholars based in United States, Switzerland and Canada. David C. Turner's co-authors include Hans M. Eppenberger, Sol M. Grüner, Ludwig Brand, Theo Wallimann, Matthias Chiquet, Thressa C. Stadtman, Mark W. Täte, Kurt R. Gehlsen, Peter T. C. So and Shyamsunder Erramilli and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

David C. Turner

121 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Quantitative estimation of protein binding site polarity. Fluorescence of N-arylaminonaphthalenesulfonates

1968 373 citations David C. Turner et al. Biochemistry profile →

Peers

Countries citing papers authored by David C. Turner

Since Specialization

Citations

This map shows the geographic impact of David C. Turner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David C. Turner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David C. Turner more than expected).

Fields of papers citing papers by David C. Turner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David C. Turner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David C. Turner. The network helps show where David C. Turner may publish in the future.

Co-authorship network of co-authors of David C. Turner

This figure shows the co-authorship network connecting the top 25 collaborators of David C. Turner. A scholar is included among the top collaborators of David C. Turner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David C. Turner. David C. Turner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL 2025 ·Clinical Pharmacology & Therapeutics ·Candice Jamois, David C. Turner, Leonid Gibiansky, (unknown), (unknown), Leonardo Pereira, Linda Lundberg, Elena Guerini, David Carlile, James Relf, Michael C. Wei, Antonia Kwan, Nicolas Frey, Susan Grange	1
2	First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors 2025 ·Journal for ImmunoTherapy of Cancer ·Michele Maio, Víctor Moreno, Juan Martín-Liberal, Frans L. Opdam, Aaron R. Hansen, Todd M. Bauer, Christophe Le Tourneau, Antoîne Italiano, Danny Rischin, Catherine Ellis, David C. Turner, Sapna Yadavilli, (unknown), Steven Hirschfeld, Marc Ballas, Iván Díaz-Padilla, Eric Angevin	1
3	Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies 2024 ·Clinical Cancer Research ·(unknown), Brendan C. Bender, Zao Li, David C. Turner, (unknown), Anton Belousov, Chi‐Chung Li	11
4	A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma 2024 ·Clinical Pharmacology & Therapeutics ·Chi‐Chung Li, Brendan C. Bender, Justin Wilkins, (unknown), David C. Turner, Bei Wang, Rong Deng, Shweta Vadhavkar, Zao Li, Antonia Kwan, Huang Huang, Kun Peng, Elicia Penuel, Ling‐Yuh Huw, Pascal Chanu, (unknown), (unknown), (unknown), (unknown)	3
5	Pharmacokinetics of biologics in gastric cancer 2023 ·Clinical and Translational Science ·(unknown), David C. Turner, Feifei Li, Xi Chen, Michael Z. Liao, Chunze Li	4
6	A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development 2023 ·Journal of Pharmacokinetics and Pharmacodynamics ·Ana Ruiz-Garcı́a, Paul Baverel, Dean Bottino, (unknown), Feng Yan, Ignacio Ferreira González, Jaeyeon Kim, Seth Robey, Indrajeet Singh, David C. Turner, (unknown), Donghua Yin, (unknown), Hao Zhu, Peter L. Bonate	28
7	11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study 2020 ·Annals of Oncology ·Eric Angevin, Stefanie L. Groenland, Todd M. Bauer, Danny Rischin, (unknown), (unknown), José Trigo, Michael Chisamore, Jafar Sadik Shaik, Fabio Rigat, (unknown), (unknown), Robert Gagnon, (unknown), David C. Turner, Sapna Yadavilli, Marc Ballas, Axel Hoos, Michele Maio	2
8	Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance 2018 ·Clinical Cancer Research ·David C. Turner, Anna Kondic, Keaven M. Anderson, Andrew Robinson, Edward B. Garon, Jonathan W. Riess, Lokesh Jain, Kapil Mayawala, Jiannan Kang, Scot Ebbinghaus, Vikram Sinha, Dinesh P. de Alwis, Julie A. Stone	156
9	A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors 2015 ·Child s Nervous System ·Mark W. Kieran, Susan Chi, Stewart Goldman, Arzu Onar‐Thomas, Tina Young Poussaint, Sridhar Vajapeyam, Frederic H. Fahey, Shengjie Wu, David C. Turner, Clinton F. Stewart, Marsha A. Moses, Roger J. Packer, Regina I. Jakacki, Anu Banerjee, James M. Boyett, Maryam Fouladi, Larry E. Kun	13
10	Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells 2014 ·Cancer Research ·Anna E. Vilgelm, Jeff S. Pawlikowski, Yan Liu, Oriana E. Hawkins, Tyler A. Davis, (unknown), Kevin P. Weller, Linda W. Horton, Colt M. McClain, Gregory D. Ayers, David C. Turner, (unknown), Clinton F. Stewart, Jeffrey A. Sosman, Mark C. Kelley, Jeffrey Ecsedy, Jeffrey N. Johnston, Ann Richmond	82
11	Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing 2014 ·Clinical Cancer Research ·David C. Turner, Fariba Navid, Najat C. Daw, Shenghua Mao, Jianrong Wu, Victor M. Santana, Michael D. Neel, Bhaskar Rao, Jennifer Willert, David M. Loeb, (unknown), Stacy L. Throm, Burgess B. Freeman, (unknown)	40
12	Population Pharmacokinetic Pharmacodynamic Modeling of Caffeine Using Visual Analogue Scales 2014 ·Pharmacology &amp Pharmacy ·(unknown), Ayyappa Chaturvedula, David C. Turner, Hailing Zhang, (unknown)	1
13	Minimally Invasive Techniques in Management of Hepatic Neuroendocrine Metastatic Disease 2009 ·American Journal of Clinical Oncology ·David Liu, Andrew S. Kennedy, David C. Turner, Steven C. Rose, Stephen T. Kee, Samuel H. Whiting, Ravi Murthy, Charles Nutting, Manraj K.S. Heran, Robert J. Lewandowski, Jesse Knight, Seza A. Güleç, Riad Salem	18
14	Diffusion and transfer of antibody proteins from a sugar-based hydrogel 1997 ·Applied Biochemistry and Biotechnology ·Michael A. Markowitz, David C. Turner, Brett D. Martin, Bruce P. Gaber	11
15	Impairment of integrin-mediated cell-matrix adhesion in oxidant-stressed PC12 cells 1994 ·Brain Research ·Zhiyuan Zhang, David C. Turner, (unknown), Daniel B. Hinshaw, Paul A. Hyslop	17
16	Effect of the chirality of the glycerol backbone on the bilayer and nonbilayer phase transitions in the diastereomers of di-dodecyl-beta-D-glucopyranosyl glycerol 1992 ·Biophysical Journal ·David A. Mannock, Rebecca Lewis, R.N. McElhaney, Morito Akiyama, (unknown), David C. Turner, Sol M. Grüner	30
17	Distribution of decane within the unit cell of the inverted hexagonal (HII) phase of lipid-water-decane systems determined by neutron diffraction 1992 ·Biochemistry ·David C. Turner, Sol M. Grüner, John S. Huang	31
18	X-ray diffraction reconstruction of the inverted hexagonal (HII) phase in lipid-water systems 1992 ·Biochemistry ·David C. Turner, Sol M. Grüner	109
19	Nonbilayer phases of membrane lipids 1991 ·Chemistry and Physics of Lipids ·Mark W. Täte, Eric F. Eikenberry, David C. Turner, Shyamsunder Erramilli, Sol M. Grüner	141
20	.alpha.1.beta.1 Integrin heterodimer functions as a dual laminin/collagen receptor in neural cells 1990 ·Biochemistry ·Nabil J. Tawil, Mario Houde, Russell Blacher, Fred Esch, Louis F. Reichardt, David C. Turner, Salvatore Carbonetto	98

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact